Biotech news on February 17, 2026

1. 0122:36 UTC

   DelveInsight reports juvenile idiopathic arthritis market forecast to 2036

   4 outlets · first: thetimesofbengal.com Pharma

   Machine summary DelveInsight published a Juvenile Idiopathic Arthritis Market Insights report covering treatment practices, emerging drugs, market share and forecasted market size from 2022 to 2036 in the United States, the EU4, the United Kingdom and Japan.

   1. The report states that leading companies such as Bristol-Myers Squibb, UCB Biopharma and Novartis are developing new juvenile idiopathic arthritis treatment drugs.
   2. The report lists promising juvenile idiopathic arthritis therapies in clinical trials including Deucravacitinib (SOTYKTU), Bimekizumab (BIMZELX) and MAS825.

   Reported by thetimesofbengal.com, weeklyvoice.com, finanznachrichten.de and Pr Newswire.

   • Novartis
   • BIMZELX
   • SOTYKTU
   • UCB Biopharma
   • DelveInsight

2. 0218:56 UTC

   Coverage recordEurekAlert!: “Classifying pediatric brain tumors by liquid biopsy using artificial intelligence”

   3 outlets · first: EurekAlert! Pharma

   Reports ran from 18:56 UTC on Feb 17 to 09:21 UTC on Feb 18.

   The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

   Reported by EurekAlert! and technologynetworks.com.

   • Artificial Intelligence
   • liquid biopsy

3. 0317:30 UTC

   AI Tool Predicts Colorectal Cancer Risk in Ulcerative Colitis Patients

   2 outlets · first: UC San Diego Today Pharma

   Machine summary Researchers at UC San Diego have developed an artificial intelligence model that accurately predicts the risk of colorectal cancer in ulcerative colitis patients with low-grade dysplasia.

   1. UC San Diego researchers developed an AI tool to predict CRC risk in patients with Ulcerative Colitis.
   2. The tool targets patients with Low-Grade Dysplasia (LGD).

   Reported by UC San Diego Today and news-medical.net.

   • Artificial Intelligence
   • UC San Diego

4. 0421:14 UTC

   Coverage recordseekingalpha.com: “Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript”

   2 outlets · first: Seeking Alpha Pharma

   Reports ran from 21:14 UTC on Feb 17 to 13:45 UTC on Feb 18.

   The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

   Reported by Seeking Alpha and Insider Monkey.

   • Genmab A/S

5. 0514:00 UTC

   SpendRule Exits Stealth with $2M to Tackle Hospital Spending Inefficiency

   2 outlets · first: techcrunch.com Funding

   Machine summary SpendRule has raised $2M and exited stealth to help hospitals track spending, according to TechCrunch and finance.yahoo.com. TechCrunch reports that it launched last summer and describes it as an AI-powered platform that assists healthcare systems in tracking spending.

   Reported by finance.yahoo.com and techcrunch.com.

   • SpendRule

6. 0618:50 UTC

   Pre-market moves reported across several exchanges

   1 outlet · first: Meyka

   Machine summary Meyka reported pre-market price and volume movements for several listed companies on 18 February 2026, including CGN.SI, SGDX.AS, MLPRX.PA, 3350.T, BeMap (4316.T) and CET.TO.

   1. Meyka reported CGN.SI volume of 2.89M pre-market at S$2.49 for 18 Feb 2026
   2. Meyka reported SGDX.AS up 10.69% pre-market on 18 Feb 2026
   3. Meyka reported MLPRX.PA (Parx Materials) up 9.76% pre-market on Euronext on 18 Feb 2026 with strong volume.
   4. Meyka reported 3350.T up 4.00% to JPY 338.00 pre-market on JPX for 18 Feb 2026
   5. Meyka reported BeMap's (4316.T, JPX) pre-market gain of 45%, reaching JPY 1,449; this was on 18 Feb 2026.

   Reported by Meyka.

   • CGN.SI
   • Parx Materials
   • BeMap

Each summary and its key facts are a machine summary of the reports linked under it; the outlets, times and counts come from those reports' own records. How a rundown is built.